drugset
drugset / Trial / NCT00528099

Study Evaluating IMA-026 in Healthy Japanese Males

NCT00528099 ↗

Phase 1 Completed 50 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupQuadruple-blindTreatment

Summary

To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending, single subcutaneous or intravenous doses of IMA-026 in healthy Japanese male subjects

Timeline

Start
2007-10
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject IMA-026 Unknown 0.3 mg/kg Subcutaneous
Subject IMA-026 Unknown 1 mg/kg Subcutaneous
Subject IMA-026 Unknown 2 mg/kg Subcutaneous
Subject IMA-026 Unknown 3 mg/kg Subcutaneous
Subject IMA-026 Unknown 4 mg/kg Subcutaneous

Indications

No indication recorded.